Cargando…

Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease

The Centers for Medicare and Medicaid Services (CMS) has recently issued a national coverage determination for US Food and Drug Administration (FDA)-approved anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease (AD) under coverage with evidence development (CED). CED sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morin, Peter J., Zhang, Quanwu, Xia, Weiming, Miller, Donald, Querfurth, Henry, Tahami Monfared, Amir Abbas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195925/ https://www.ncbi.nlm.nih.gov/pubmed/36933140 http://dx.doi.org/10.1007/s40120-023-00462-z

Ejemplares similares

Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System
por: Morin, Peter, et al.
Publicado: (2022)

Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Alzheimer’s Disease: Epidemiology and Clinical Progression
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Humanistic and Economic Burden of Alzheimer's Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Correction to: Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Understanding Barriers Along the Patient Journey in Alzheimer’s Disease Using Social Media Data
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Factors Driving the Transition of Alzheimer’s Disease Patients to Institutional Long-term Care
por: Davila, Heather, et al.
Publicado: (2021)

Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System
por: Aguilar, Byron J., et al.
Publicado: (2023)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Estimating Transition Probabilities Across the Alzheimer’s Disease Continuum Using a Nationally Representative Real-World Database in the United States
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors
por: Dranitsaris, George, et al.
Publicado: (2022)

Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
por: Dranitsaris, George, et al.
Publicado: (2023)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2019)

Scientific Challenges in the Risk Assessment of Food Contact Materials
por: Muncke, Jane, et al.
Publicado: (2017)

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
por: Quon, Peter L., et al.
Publicado: (2019)

Chemical datuments as scientific enablers
por: Rzepa, Henry S
Publicado: (2013)

Low Dose Medicine: theoretical background and scientific evidence
por: Bernasconi, S.
Publicado: (2018)

'Libyan Trial': a verdict running counter to scientific evidence
por: Fleutelot, Eric
Publicado: (2006)

Evidence-Informed Deliberative Processes for Universal Health Coverage: Broadening the Scope: Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness"
por: Gopinathan, Unni, et al.
Publicado: (2016)

Global Neglect of Dental Coverage in Universal Health Coverage Systems and Japan's Broad Coverage
por: Aida, Jun, et al.
Publicado: (2021)

Challenges and Solutions Surrounding Environmental Enrichment for Dogs and Cats in a Scientific Environment
por: Desforges, Emma
Publicado: (2021)

Weight cycling in combat sports: revisiting 25 years of scientific evidence
por: Lakicevic, Nemanja, et al.
Publicado: (2021)

Indian PM’s evidence based wellness approach inspires politico-scientific activism
por: Nagendra, H R, et al.
Publicado: (2019)

Ethical priority setting for universal health coverage: challenges in deciding upon fair distribution of health services
por: Norheim, Ole F.
Publicado: (2016)

Priority Setting for Universal Health Coverage: We Need to Focus Both on Substance and on Process: Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, not Just More Evidence on Cost-Effectiveness"
por: Lauer, Jeremy A., et al.
Publicado: (2017)

Universal Health Coverage, Non-communicable Disease, and Equity: Challenges to Implementation Comment on "Universal Health Coverage for Non-communicable Diseases and Health Equity: Lessons From Australian Primary Healthcare"
por: Woodruff, Tim
Publicado: (2021)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Undefined cellulase formulations hinder scientific reproducibility
por: Himmel, Michael E., et al.
Publicado: (2017)

There is no evidence that vitamin D supplementation drives the progression of Alzheimer's disease
por: Gombart, Adrian F., et al.
Publicado: (2022)

Towards universal health coverage: can national health research systems deliver contextualised evidence to guide progress in Africa?
por: Nabyonga-Orem, Juliet, et al.
Publicado: (2019)

Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward
por: Lawal, Lukman, et al.
Publicado: (2022)

Moving from rhetoric to action: how Africa can use scientific evidence to halt the COVID-19 pandemic
por: Olu, Olushayo Oluseun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_paqifot65cukq3dnpluhm86jsa